Skip to navigation Skip to content

Patriot News Organization

patriotnewsorganization.com

Primary Menu
  • Health News
  • Home
  • VP-102
Verrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts (CARE-1)
Health News

Verrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts (CARE-1)

11/16/2020

WEST CHESTER, Pa., November 10, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced positive topline results from its Phase 2 CARE-1 clinical study of…

Read More
Recent Posts
  • Special requirements for cleaning medical center windows
  • How to calculate a moving budget
  • UKHSA and ONS publish latest Winter CIS data
  • Exploring artificial general intelligence for radiation oncology
  • New study sheds light on the connection between the microbiome and kidney stones
Copyright © All rights reserved. 2025 Patriot News Organization.
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok